clinical trial · NCT03723655
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Bristol-Myers Squibb·phase3·completed·n = 314
Hypertrophic CardiomyopathyObstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic Cardiomyopathymavacamten
brief summary
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
started
Sep 27, 2018
primary completion
Jan 16, 2026
completion
Jan 16, 2026
last updated
Feb 20, 2026
official title
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol